Premium
Delayed‐Onset Ticlopidine‐Induced Cholestatic Jaundice
Author(s) -
Kubin Christine J.,
Sherman Olga,
Hussain Khozema B.,
Feinman Lawrence
Publication year - 1999
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.19.11.1006.31567
Subject(s) - cholestatic jaundice , ticlopidine , jaundice , medicine , gastroenterology , clopidogrel , aspirin
An 86‐year‐old man experienced a rash approximately 2 weeks after starting ticlopidine therapy, necessitating discontinuation of the drug. About 1 month later, despite discontinuation, he developed jaundice and liver test abnormalities. These resolved gradually over the next few months. Based on case reports and the drug's pharmacokinetic profile, a high index of suspicion for ticlopidine‐induced jaundice is prudent in patients with recent exposure to the agent who have evidence of liver damage.